The Impact of Neoadjuvant Chemotherapy on Implant-Based Breast Reconstruction Outcomes.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
2013 patients were included, of whom 1202 (59.
I · Intervention 중재 / 시술
immediate TE-based breast reconstruction between 2017 and 2022 were included
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] NACT is a significant predictor of TE loss but does not prolong the commencement to radiotherapy. The increased rate of TE loss among the NACT group may reflect a higher rate of adjuvant radiation treatment and the combination of the deleterious effects of NACT and radiation therapy on wound healing.
[BACKGROUND] Neoadjuvant chemotherapy (NACT) is a critical component of breast cancer treatment, yet its impact on tissue expander (TE)-based breast reconstruction remains unclear.
- p-value P < 0.001
- 95% CI 1.47 to 3.93
APA
Kim M, Barnett JM, et al. (2026). The Impact of Neoadjuvant Chemotherapy on Implant-Based Breast Reconstruction Outcomes.. Plastic and reconstructive surgery, 157(4), 593-602. https://doi.org/10.1097/PRS.0000000000012415
MLA
Kim M, et al.. "The Impact of Neoadjuvant Chemotherapy on Implant-Based Breast Reconstruction Outcomes.." Plastic and reconstructive surgery, vol. 157, no. 4, 2026, pp. 593-602.
PMID
40875534 ↗
Abstract 한글 요약
[BACKGROUND] Neoadjuvant chemotherapy (NACT) is a critical component of breast cancer treatment, yet its impact on tissue expander (TE)-based breast reconstruction remains unclear. The purpose of this study was to examine the impact of NACT on complication rates after immediate TE-based breast reconstruction and on the commencement of adjuvant radiotherapy.
[METHODS] Female patients who underwent immediate TE-based breast reconstruction between 2017 and 2022 were included. Inclusion criteria consisted of patients who completed NACT within 2 months of mastectomy and those who did not receive chemotherapy. Patients who underwent bilateral prophylactic mastectomy, delayed reconstruction, adjuvant chemotherapy, and neoadjuvant radiation therapy were excluded.
[RESULTS] A total of 2013 patients were included, of whom 1202 (59.7%) received NACT, and 811 (40.3%) did not receive chemotherapy. The rate of TE loss was significantly higher in the NACT cohort than in the control cohort (9.8% versus 3.9%; P < 0.001). Multivariable regression models showed that NACT significantly increases the rate of TE loss (OR, 2.39; 95% CI, 1.47 to 3.93; P < 0.001) but no other complications, including cellulitis. NACT did not delay the commencement to radiation therapy. However, patients who developed cellulitis started radiation therapy on average 17 days later than those who did not (95% CI, 3.5 to 31; P = 0.014).
[CONCLUSIONS] NACT is a significant predictor of TE loss but does not prolong the commencement to radiotherapy. The increased rate of TE loss among the NACT group may reflect a higher rate of adjuvant radiation treatment and the combination of the deleterious effects of NACT and radiation therapy on wound healing.
[METHODS] Female patients who underwent immediate TE-based breast reconstruction between 2017 and 2022 were included. Inclusion criteria consisted of patients who completed NACT within 2 months of mastectomy and those who did not receive chemotherapy. Patients who underwent bilateral prophylactic mastectomy, delayed reconstruction, adjuvant chemotherapy, and neoadjuvant radiation therapy were excluded.
[RESULTS] A total of 2013 patients were included, of whom 1202 (59.7%) received NACT, and 811 (40.3%) did not receive chemotherapy. The rate of TE loss was significantly higher in the NACT cohort than in the control cohort (9.8% versus 3.9%; P < 0.001). Multivariable regression models showed that NACT significantly increases the rate of TE loss (OR, 2.39; 95% CI, 1.47 to 3.93; P < 0.001) but no other complications, including cellulitis. NACT did not delay the commencement to radiation therapy. However, patients who developed cellulitis started radiation therapy on average 17 days later than those who did not (95% CI, 3.5 to 31; P = 0.014).
[CONCLUSIONS] NACT is a significant predictor of TE loss but does not prolong the commencement to radiotherapy. The increased rate of TE loss among the NACT group may reflect a higher rate of adjuvant radiation treatment and the combination of the deleterious effects of NACT and radiation therapy on wound healing.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Endoscopic Submucosal Dissection (ESD) Offers a Safer and More Cost-effective Alternative to Transanal Endoscopic Microsurgery (TEM): An International Collaborative Study.
- A Phase II Study of Durvalumab, Doxorubicin, and Ifosfamide in Recurrent and/or Metastatic Pulmonary Sarcomatoid Carcinoma (KCSG LU-19-24).
- USP21-mediated SMARCB1 stabilization under hypoxia may influence tumor progression and immune response in HCC.
- Elimusertib, a Novel ATR Inhibitor, Induces Anti-tumor Effects through Replication Catastrophe in Breast Cancers.
- Thyroglobulin Cutoffs after Total Thyroidectomy Without Radioiodine in Low- to Intermediate-Risk Thyroid Cancer: A Multicenter Cohort Study.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.